EPO Case: Peres Jepchirchir Provisionally Suspended, Sydney Marathon Title Under a Cloud

Before the clock read two hours, 18 minutes and 31 seconds in Sydney, a sample sent from Kenya had already reached the desk of the Athletics Integrity Unit. An out-of-competition sample. It tested positive for EPO. Now Peres Jepchirchir, Olympic and World Championships marathon gold medallist, is provisionally suspended. The announcement came 18 days after the race she won by more than three minutes. For a reporter of my vintage this is not a new story; since 2026 I have logged the stopwatch and the sample slip in the same register. But every time a leading distance runner makes headlines this way, the question stays the same: did we read the time first, or the document? Jepchirchir's record needs no introduction. Olympic women's marathon champion at Tokyo 2026, then world champion in the same city in September 2026. World half-marathon record in 2026, broken three more times in 2026. Wins in New York 2026, Boston 2026, London 2026. The Sydney Marathon became the seventh world major in 2026, and on 30 August 2026 she won it in 2:18:31, more than three minutes clear of compatriot Irene Chepet Cheptai. That is the title now sitting under an administrative cloud. The technical side matters. EPO, erythropoietin, is a natural substance produced in the kidneys that stimulates the creation of new red blood cells. Injected, it is detectable in urine or blood only for a short window, and it raises the red blood cell count, increasing oxygen delivery to the muscles. That is both its appeal and its problem — the wider the gap between dose and test, the weaker the catch. Which is why in EPO cases the when, the where and the which-lab matter more than the time. There is a sequencing detail here that cannot be waved away. The sample was collected in Kenya before the race. So while 2:18:31 was going onto the clock in Sydney, a testing process was already in motion. The result was announced later, but the gap between the watch and the paper is the real story of this case. The AIU's provisional suspension procedure rests on exactly that gap: sample, result, notification, suspension. I remember the evening at the 2026 World Championships in Paris when, after Anju Bobby George's bronze, I walked to the IAAF media desk and asked for the full six-attempt sheet. Her five legal marks sat inside a 22-centimetre band — the tightest series in the top eight. That day I learned that a result sheet is never enough; you need the raw data. In an EPO case the lesson runs in reverse — here the raw data is a sample, and it comes before the mark. The question is not whether 2:18:31 was fast. The question is what the biological record behind that time says. There is a page in my forty-year register I keep turning back to. At the 2026 Delhi Commonwealth Games I watched Krishna Poonia win discus gold at the Jawaharlal Nehru Stadium. Eighteen months later, six Indian women athletes — including members of the 4x400 relay squad — took CAS-confirmed bans from 2026 tests. That day I stopped writing eulogies, drafted a one-page supplement-declaration protocol, mailed it to fourteen state units, and filed a three-part audit. That experience taught me that protocol is what we agreed to while we were still calm. In an EPO case, that calm protocol is now on trial. The easy route here is to erase the entire legacy of a 33-year-old runner in one stroke. That would be wrong, and it would be just as wrong to assume an Olympic gold puts anyone above testing. Jepchirchir was Olympic champion in Tokyo and world champion in the same city in September 2026 — those facts stand where they stand, and the EPO sample stands where it stands. A provisional suspension does not mean guilt has been established; it means the process has begun. The B sample, the hearing, the verdict — all of that is ahead. Those pronouncing a final verdict now are in the same hurry I have spent forty years avoiding. But there is a second hurry — the claim that because the sample was taken before the race, the win is beyond question. That argument is convenient, not logical. If the sample is positive and that period connects to the performance, the validity of the title is itself in question. On the other hand, if the testing process turns out to be flawed, the suspension can be lifted just as quickly. Both possibilities are open, and both deserve the same standard of measurement. What gets the least discussion in all of this is the technical limit of EPO testing. The substance is detectable only in a short window, which is why the AIU leans on out-of-competition testing — like this sample in Kenya. The question is whether the timing, location and chain of custody are documented the way every split is documented in my register. If they are, the case is strong. If not, it is a headline that will expire before it becomes a legal document. I have always said the watch never lied to me, so I stopped lying to it. But a watch only tells the time; it does not tell you how the time was made. 2:18:31 is a number; the blood chemistry behind that number is a separate document. They cannot share a single column. Put in one column what the result sheet, the wind reading and the sample report say; in the other, what we wished had happened. The gap will show itself. For Kenya this is not an isolated event. Over the past decade the Kenyan marathon corps has repeatedly featured in EPO and other prohibited-substance cases, and each case has added a layer to the country's long-distance tradition. But I will not fall into the trap of judging an entire nation's sport by one athlete's sample. Kenya's depth is in its track record, its camps and its training culture. One case is one case. For the Sydney Marathon organisers the position is more delicate still. The race became a world major in 2026, and for the first time its reputation is on the line. A question over the winner's sample means prize money, the record book and sponsor relationships all face review. Winning major status is easy; keeping it is not. The question that troubles me most: if this case holds up, is the Sydney title annulled? And if it is, does Irene Chepet Cheptai get the title, or is the race declared vacant? These are purely hypothetical for now, because no final decision has been made. But they are a signal of how ready the sport's administrative machinery is for cases like EPO. I think back to my 2026 register, when I was covering the Seoul Asian Games from a Delhi office. Hand-timing every P.T. Usha final, I logged 214 splits across eleven events. The desk asked for 300 words; I filed the splits first and the adjectives second. After that week I never filed a track story without a number. In an EPO case the number is a sample, and the adjectives have not even been written yet. What next? The B sample, the hearing, and possibly a CAS appeal. The process will take months, and participation will be on hold in the meantime. In the coming months' marathon preview tables, her name will not appear — that is fact, not opinion. The bigger question is whether the athletics world takes from this case the lesson that the number and quality of out-of-competition tests for substances like EPO must increase, or whether we will repeat the same old debate with a new name each time. One column in my register is what happened; the other is what we wished had. The Sydney Marathon of 30 August 2026 has written 2:18:31 in the first column. The second column is still blank, and filling it is the job of the testing process, not mine. I will keep the register open until then.